The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.

See all 354 in Finance →

By

Leave a Reply

Your email address will not be published. Required fields are marked *